Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Brivanib

Home DrugsBrivanib

Investigational

Small Molecule

Brivanib

Unknown Manufacturer

Brivanib is under investigation for the treatment of HepatoCellular Carcinoma. Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC).

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

Brivanib is under investigation for the treatment of HepatoCellular Carcinoma. Brivanib has been investigated for the treatment of Solid Tumors, Hepato Cellular Carcinoma (HCC), and Metastatic Colorectal Cancer (MCRC).

Technical identifiers

Chemical Formula: C₁₉H₁₉FN₄O₃
CAS Number: 649735-46-6
UNII ID: DDU33B674I

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Application of small-molecular compound in preparation of lung cancer chemosensitization drug
CN 110917199 AApplicant: SHANGHAI PULMONARY HOSPITALPriority: 2019
CN